drugset / Trial / NCT07380386

SKB105 for Injection in Advanced Solid Tumors

NCT07380386 ↗

Phase 1/2 Recruiting 256 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1/2 clinical study to evaluate the safety and efficacy of SKB105 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.

Timeline

Start
2026-03-05
Primary completion
2029-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SKB105 Other / unclassified — Intravenous

Indications